Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 2
Treatment-assignment count: 1
Stratification count: 0
Drug Development Ahead Of Cdx Context
BRCA1/2 mutation
solid tumor basket · Monoclonal Antibody
BRCA1/2 mutation is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 3 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: HER2-low | HER2-low | dMMR
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT05417594 | https://clinicaltrials.gov/study/NCT02715284 | https://clinicaltrials.gov/study/NCT02693535